--- title: "What's Going On With Black Diamond Therapeutics Stock Tuesday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/287658689.md" description: "Black Diamond Therapeutics (NASDAQ: BDTX) stock rose 3.51% to $2.36 on Tuesday, following positive Phase 2 data for silevertinib in NSCLC patients. The company reported a first-quarter loss of 16 cents per share, better than expected. Analysts maintain a Buy rating with an average price target of $11.00. Despite recent volatility, the stock shows a 12-month performance of 11.22%. The findings will be presented at the ASCO Annual Meeting on May 30, 2026." datetime: "2026-05-26T15:31:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287658689.md) - [en](https://longbridge.com/en/news/287658689.md) - [zh-HK](https://longbridge.com/zh-HK/news/287658689.md) --- # What's Going On With Black Diamond Therapeutics Stock Tuesday? **Black Diamond Therapeutics, Inc.** (NASDAQ:BDTX) stock climbed in Tuesday's session. The company recently reported encouraging Phase 2 data for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations. The clinical-stage oncology company said the Phase 2 results support silevertinib's potential as a practice-changing treatment for NSCLC patients with EGFR non-classical mutations, with promising preliminary progression-free survival data. The findings are scheduled to be presented at the ASCO Annual Meeting on May 30, 2026. ## Black Diamond Therapeutics Earnings Snapshot Earlier this month, Black Diamond Therapeutics reported a first-quarter loss of 16 cents per share, beating Wall Street estimates for a loss of 18 cents per share. Research and development expenses declined to $7 million from $10.5 million a year ago, primarily due to progress in the Phase 2 silevertinib NSCLC trial and the outlicensing of BDTX-4933 as the company sharpened its focus on silevertinib development. As of March 31, 2026, the company held $118.3 million in cash, cash equivalents and investments, which management said is expected to fund operations into the second half of 2028. ## BDTX Technical Analysis: Trend, Moving Averages And Momentum Currently, BDTX is trading at $2.36. This places it 16.2% below its 20-day simple moving average (SMA) of $2.84 and 9.7% below its 50-day SMA of $2.63. The stock has seen a 12-month performance of 11.22%, indicating some resilience over the longer term despite recent volatility. The moving averages present a mixed picture. While the 20-day SMA is above the 50-day SMA, indicating a bullish short-term trend, the 50-day SMA is below the 200-day SMA, signaling a death cross that could suggest longer-term bearish sentiment. For momentum analysis, the MACD is currently below its signal line, indicating that momentum is fading, which could suggest caution for traders looking for upward movement. ## What Black Diamond Therapeutics (BDTX) Does Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of the company has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), is currently being studied in a Phase 2 clinical trial in patients with EGFR mutant non-small cell lung cancer (NSCLC). ## Analyst Consensus & Recent Actions The stock carries a Buy rating with an average price forecast of $11.00. Recent analyst moves include: - **BTIG**: Buy (Raises forecast to $11.00) (April 29) - **Wedbush**: Outperform (Raises forecast to $14.00) (March 17) - **Piper Sandler**: Overweight (Lowers forecast to $8.00) (January 16) ## Black Diamond Therapeutics Price Action **BDTX Stock Price Activity:** Black Diamond Therapeutics shares were up 3.51% at $2.36 during premarket trading on Tuesday, according to Benzinga Pro data. _Photo via Shutterstock_ ### Related Stocks - [BDTX.US](https://longbridge.com/en/quote/BDTX.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) ## Related News & Research - [Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path](https://longbridge.com/en/news/288927469.md) - [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md) - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) - [Black Diamond Therapeutics Q2 net loss narrows year over year](https://longbridge.com/en/news/295007104.md) - [Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 2% - Should You Buy?](https://longbridge.com/en/news/282135498.md)